Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - lidocaine hydrochloride monohydrate, quantity: 213.2 mg (equivalent: lidocaine hydrochloride, qty 200 mg) - injection, solution - excipient ingredients: water for injections; sodium chloride; hydrochloric acid; sodium hydroxide - for production of local or regional anaesthesia by nerve block, infiltration injection, caudal or other epidural blocks. treatment or prophylaxis of life-threatening ventricular arrhythmias, including those associated with myocardial infarction, general anaesthesia in patients predisposed to ventricular arrhythmias, digitalis intoxication, or following resuscitation from cardiac arrest.

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - lidocaine hydrochloride monohydrate, quantity: 42.66 mg (equivalent: lidocaine hydrochloride, qty 40 mg) - injection, solution - excipient ingredients: sodium hydroxide; water for injections; sodium chloride; hydrochloric acid - for production of local or regional anaesthesia by nerve block, infiltration injection, caudal or other epidural blocks. treatment or prophylaxis of life-threatening ventricular arrhythmias, including those associated with myocardial infarction, general anaesthesia in patients predisposed to ventricular arrhythmias, digitalis intoxication, or following resuscitation from cardiac arrest.

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - lidocaine hydrochloride monohydrate, quantity: 21.32 mg (equivalent: lidocaine hydrochloride, qty 20 mg) - injection, solution - excipient ingredients: sodium hydroxide; sodium chloride; hydrochloric acid; water for injections - for production of local or regional anaesthesia by nerve block, infiltration injection, caudal or other epidural blocks. treatment or prophylaxis of life-threatening ventricular arrhythmias, including those associated with myocardial infarction, general anaesthesia in patients predisposed to ventricular arrhythmias, digitalis intoxication, or following resuscitation from cardiac arrest.

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - lidocaine hydrochloride monohydrate, quantity: 426.6 mg (equivalent: lidocaine hydrochloride, qty 400 mg) - injection, solution - excipient ingredients: sodium chloride; hydrochloric acid; water for injections; sodium hydroxide - for production of local or regional anaesthesia by nerve block, infiltration injection, caudal or other epidural blocks. treatment or prophylaxis of life-threatening ventricular arrhythmias, including those associated with myocardial infarction, general anaesthesia in patients predisposed to ventricular arrhythmias, digitalis intoxication, or following resuscitation from cardiac arrest.

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - lidocaine hydrochloride monohydrate, quantity: 106.65 mg (equivalent: lidocaine hydrochloride, qty 100 mg) - injection, solution - excipient ingredients: sodium chloride; sodium hydroxide; hydrochloric acid; water for injections - for production of local or regional anaesthesia by nerve block, infiltration injection, caudal or other epidural blocks. treatment or prophylaxis of life-threatening ventricular arrhythmias, including those associated with myocardial infarction, general anaesthesia in patients predisposed to ventricular arrhythmias, digitalis intoxication, or following resuscitation from cardiac arrest.

New Zealand - Inggeris - Medsafe (Medicines Safety Authority)

baxter healthcare ltd - doxorubicin hydrochloride 2 mg/ml (actual amount depends on total phosphate assay);   - concentrate for infusion - 2 mg/ml - active: doxorubicin hydrochloride 2 mg/ml (actual amount depends on total phosphate assay)   excipient: ammonium sulfate carbamoyl-methoxypolyethylene glycol distearoyl glycerophosphoethanolamine sodium cholesterol histidine lecithin sucrose water for injection - · metastatic breast cancer in women for whom an anthracycline would be considered · metastatic breast cancer in women who have failed a taxane-containing regimen

New Zealand - Inggeris - Medsafe (Medicines Safety Authority)

baxter healthcare ltd - ondansetron hydrochloride dihydrate 2.49 mg/ml equivalent to 2 mg ondansetron - solution for injection - 2 mg/ml - active: ondansetron hydrochloride dihydrate 2.49 mg/ml equivalent to 2 mg ondansetron excipient: citric acid monohydrate sodium chloride sodium citrate dihydrate water for injection - the prevention and treatment of nausea and vomiting induced by cytotoxic therapy and radiotherapy.

New Zealand - Inggeris - Medsafe (Medicines Safety Authority)

baxter healthcare ltd - midazolam 1 mg/ml - solution for injection - 1 mg/ml - active: midazolam 1 mg/ml excipient: hydrochloric acid hydrochloric acid (ph adjuster) sodium chloride sodium hydroxide water for injection - premedication before induction of anaesthesia (i.m. or, especially in children, rectal, intranasal or oral administration).

New Zealand - Inggeris - Medsafe (Medicines Safety Authority)

baxter healthcare ltd - midazolam 5 mg/ml - solution for injection - 5 mg/ml - active: midazolam 5 mg/ml excipient: hydrochloric acid hydrochloric acid (ph adjuster) sodium chloride sodium hydroxide water for injection - premedication before induction of anaesthesia (i.m. or, especially in children, rectal, intranasal or oral administration).

New Zealand - Inggeris - Medsafe (Medicines Safety Authority)

baxter healthcare ltd - hyoscine 1.5mg (supplied as hyoscine (scopolamine) hydrobromide trihydrate);   - transdermal patch - 1mg/72 hours - active: hyoscine 1.5mg (supplied as hyoscine (scopolamine) hydrobromide trihydrate)   - the prevention of symptoms of motion sickness, such as nausea, vomiting and vertigo, which can occur when traveling.